Fycompa Titration Intervals and Effects on Retention Rate

Epilepsy Clinical Trial

Official title:

Fycompa Titration Intervals and Effects on Retention Rate

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03457129
• Other study ID #: Fycompa Titration IIS
• Status: Completed
• Phase: Phase 4
• Start date: April 18, 2018
• Est. completion date: December 15, 2021

Study information

• Verified date: July 2023
• Source: University of Arizona
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will aim to improve retention and tolerability by slowing the initial titration rate of perampanel from a standard up-titration rate of 2 week intervals to a slower up-titration rate consisting of 3 week intervals. Subjects will be randomized to either perampanel, standard titration interval rate (Group A) or perampanel, slower titration interval rate (Group B).

Description:

A total of 60 subjects with a confirmed diagnosis of either partial onset or primary generalized epilepsy will be recruited into the trial. 30 subjects will initiate perampanel at a dose of 2 mg/day and titrate upwards every 2 weeks to a target dose of 6 mg/day. Subjects in this group will be designated Group A. The remaining 30 subjects will also begin perampanel at a dose of 2 mg/day but will titrate upwards every 3 weeks to a target dose of 6 mg/day and will be designated Group B.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 15, 2021
• Est. primary completion date: February 24, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Must provide written informed consent signed by the subject or legal guardian prior to entering the study in accordance with ICH and GCP guidelines.

2. Subject has a confirmed diagnosis of medically refractory epilepsy with or without secondary generalization for at least 12 months prior to visit 1.

3. Subjects currently being treated with 1 to 3 antiepileptic medications with or without VNS (does not count as an AED).

4. Subjects aged 18 to 75.

5. Subject's requiring an additional epilepsy medication due to either uncontrolled seizures and/or lack of tolerability with current epilepsy medications.

6. Can be safely treated, in the opinion of the investigator, with Fycompa.

7. Able and agrees to follow the specified titration schedule.

8. Subjects or a legal guardian who is able to communicate effectively with study personnel and considered reliable, able, willing and cooperative with regard to complying with protocol-defined requirements, including completion of the study diary.

Exclusion Criteria:

1. Any history of non-epileptic or psychogenic seizures.

2. Women who are currently pregnant, lactating or have plans to become pregnant in the immediate future.

3. Subjects with active suicidal ideation or behavior as evidenced by positive answers on the Columbia Suicide Severity Rating Scale (C-SSRS) or subject's with a history of suicidal ideation or attempt within 12 months.

4. Subjects with a suicidal attempt in the 12 months prior to Visit 1

5. Any clinically significant medical or psychiatric illness, psychological or behavioral problems, which in the opinion of the investigator would interfere with the subject's ability to participate in the study.

6. Subjects with severe hepatic impairment or severe renal impairment or on hemodialysis.

7. Any use of concomitant medication as listed in the drug insert, including medications known to be inducers of cytochrome P450 (CYP3A).

Related Conditions & MeSH terms

• Epilepsy

Intervention

Drug:
• Perampanel Oral Tablet
Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.

Locations

Country	Name	City	State
United States	Banner University Medical Center Phoenix	Phoenix	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
University of Arizona	Eisai Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percentage of Subjects Completing 52 Weeks of Adjunctive Therapy During the Maintenance Phase [Retention Rate].	Retention rate, which indirectly measures the therapeutic tolerance, will be measured at 52 weeks in each group.	Up to 52 weeks
Secondary	Incidence of Treatment-Emergent Adverse Events (TEAEs) Reported by the Subject or Observed by the Investigator [Safety and Tolerability].	Adverse events experienced in each group will be tabulated and the total percentage of subjects reporting adverse events will be calculated.	Up to 52 weeks
Secondary	Seizures Frequency Per Week	The average of seizures per week will be calculated starting at initial titration through final maintenance [Efficacy]."	Up to 52 weeks